Cyrus Biotechnology is a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, we are developing an early pipeline of innovative programs in multiple indications. We are also partnering with leading biotech and pharma companies and research institutes to bring collaborative programs forward from discovery to the clinic. Cyrus is based on core software from the lab of David Baker at the University of Washington. We’ve worked with over 90 industry partners. We are based in Seattle, WA and financed by leading US and Asian Biotech and Tech investors including Orbimed, Trinity Ventures, Springrock, Agent Capital, iSelect, Yard Ventures, WRF and Alexandria. We are hiring! https://cyrusbio.com/careers/
Looking for a particular Cyrus Biotechnology employee's phone or email?
The Cyrus Biotechnology annual revenue was $5.3 million in 2026.
Lucas Nivon is the CEO and Co-Founder of Cyrus Biotechnology.
21 people are employed at Cyrus Biotechnology.
Cyrus Biotechnology is based in Seattle, Washington.
The NAICS codes for Cyrus Biotechnology are [518, 51, 541, 54171, 5417, 54, 541713].
The SIC codes for Cyrus Biotechnology are [87, 737, 873, 73].